SML3059
Lacosamide
≥98% (HPLC), sodium channel modulator, powder
别名:
(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide, ADD 243037, ADD-243037, ADD243037, Erlosamide, LCM, SPM-927, SPM927
登录并加购，请在购物车里查看协议价、货期和发货地。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
产品名称
Lacosamide, ≥98% (HPLC)
Quality Segment
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D 13 to 18° (C=0.5g/100mL, MeOH)
drug control
USDEA Schedule V
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
N([C@H](COC)C(=O)NCc1ccccc1)C(=O)C
InChI
1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
InChI key
VPPJLAIAVCUEMN-GFCCVEGCSA-N
Biochem/physiol Actions
Lacosamide is an orally active anticonvulsant that blocks voltage-gated sodium channels (VGSCs) selectively in their inactivated state (IC50 = 16 μM/Nav1.8, 182 μM/Nav1.7, 415 μM/Nav1.3) over resting state by enhancing slow inactivation. In addition to in vivo anticonvulsant activity (ED50 = 4.5 mg/kg in mice via i.p., 3.9 mg/kg in rats via p.o. by maximal electroshock seizure test), lacosamide also shows therapeutic efficacy in various pain models (10-30 mg/kg in rats via i.p.).
Orally active anticonvulsant that blocks voltage-gated sodium channels (VGSCs) selectively in inactivated over resting state by enhancing slow inactivation.
Still not finding the right product?
Explore all of our products under Lacosamide
警示词
Warning
危险代码
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
怎么回事？
WGK 3
闪点 (F)
Not applicable
闪点 (°C)
Not applicable